Month: November 2022

On February 13, 2014, Stoessel, Philipp; Joosten, Dominik; Breuning, Esther; Kaiser, Joachim published a patent.Electric Literature of 39919-70-5 The title of the patent was Cyclometalated iridium and platinum complexes as phosphorescent emitters for organic electroluminescent devices. And the patent contained the following:

Iridium and platinum complexes with bi- and tridentate cyclometalated ligands [(Cy1-Cy2-Q)mMLn] (1, Cy1, Cy2 = preferably aromatic cycles, condensed with aliphatic bicyclic systems, bound through heteroatom and carbon, resp., preferably, pyridine, quinoline, phenanthridine, azole derivatives, Q = optional donor-containing group, L = auxiliary ligand; preferably, L = acetylacetonato, picolinato), useful as triplet-emitting dopants or additives for light-emitting layers in organic light-emitting devices, preferably short-wave emitters, as green or blue emitters, were prepared by cyclometalation of the corresponding proligands Cy1-Cy2H-Q with properly chosen metal precursors, such as PtCl2, K2PtCl4, PtCl2(DMSO), PtMe2(DMSO)2, PtCl2(NCPh)2, and subsequent ligand substitution for introduction of the auxiliary ligands L. In an example, solvent-free reaction of 10 mmol of tris(acetylacetonato)iridium with 60 mmol of 1-(1,1,2,2,3,3-tetramethyl-5-indanyl)isoquinoline for 100 h at 230° gave the invented complex (1a, shown as I) with 42% yield. In another example, test electroluminescent device, manufactured according to standard procedure with a light-emitting layer doped with 5% of the complex 1a exhibited electroluminescence with external quantum efficiency of 15.5% at 1000 cd/m2 at working voltage of 3.0 V with CIE(x,y) coordinates of 0.68,0.32 featuring lifetime of 18000 h. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Electric Literature of 39919-70-5

The Article related to iridium platinum cyclometalated heterocyclic bicyclic complex preparation phosphorescent emitter, electroluminescent device organic platinum iridium cyclometalated complex emitter and other aspects.Electric Literature of 39919-70-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 21, 1995, Inaba, Minoru; Osa, Yumi; Ogumi, Zempachi published an article.Related Products of 52243-87-5 The title of the article was Raman spectroscopic analysis of electrochemical behavior of propylviologen in Nafion. And the article contained the following:

The electrochem. and Raman spectroscopic characteristics of propylviologen incorporated into Nafion film coated on a silver electrode were studied. The results were compared with those on silver in solutions containing Triton X-100, cetyltrimethylammonium bromide (CTAB) and sodium dodecyl sulfate (SDS) micelles. Propylviologen incorporated into Nafion showed unusual electrochem. and Raman spectroscopic behavior. The half-wave potential for the 2nd step was shifted in the neg. direction with respect to that in an aqueous solution, and only a small amount of the doubly reduced form was detected by Raman spectroscopy. Similar behavior was observed in the anionic SDS micellar solution From the observed similarity, the residence sites of propylviologen in Nafion are discussed. The experimental process involved the reaction of 1,1′-Dipropyl-[4,4′-bipyridine]-1,1′-diium bromide(cas: 52243-87-5).Related Products of 52243-87-5

The Article related to raman spectroscopy electrochem behavior propylviologen nafion, silver electrode nafion film incorporated propylviologen, micellar solution propylviologen reduction silver electrode and other aspects.Related Products of 52243-87-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 31, 1990, Kaczmarek, Lukasz; Nantka-Namirski, Pawel published an article.Name: [2,2′-Bipyridine]-3,3′-diamine The title of the article was Synthesis of N-monosubstituted [2,2′-bipyridyl]-3,3′-diamines. And the article contained the following:

The cyclocondensation reaction of 2,2′-bipyridiyl-3,3′-diamine with PhC(:NH)OEt.HCl gave 6-phenyl-5H-dipyrido[3,2-d:2′,3′-f][1,3]diazepine. Alkylation of the latter gave N-benzoyl-N’-alkyl-2,2′-bipyridiyl-3,3′-diamines which upon hydrolysis gave N-alkyl-2,2′-bipyridiyl-3,3′-diamines I [R = Bu, Me2NCH2CH2CH2, [3-(4-chlorophenyl-1-piperazinyl)propyl]]. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Name: [2,2′-Bipyridine]-3,3′-diamine

The Article related to bipyridiyldiamine cyclocondensation benzimidate, dipyridodiazepine phenyl alkylation, diazepine phenyldipyrido alkylation, alkylation phenyldipyridodiazepine, alkylbipyridiyldiamine and other aspects.Name: [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 30, 1982, McPheat, W. L.; Wardlaw, A. C. published an article.Related Products of 636-73-7 The title of the article was Inhibition of nicotinic acid and nicotinamide uptake into Bordetella pertussis by structural analogs. And the article contained the following:

The nicotinic acid (I) and nicotinamide (II) structural analogs, 3-pyridinecarboxaldehyde (III) and 3-pyridinealdoxime (IV) (both 500 and 50 μM), but not isonicotinamide, isonicotinic acid, 6-aminonicotinic acid, 6-aminonicotinamide, isoniazid, 3-acetylpyridine, 3-pyridylacetic acid, N,N-diethylnicotinamide, or 3-pyridinesulfonic acid, were effective and specific inhibitors of the uptake of I and II by B. pertussis, although neither compound inhibited the growth of the bacteria in liquid medium or the oxidation of glutamate by washed suspensions. 3-Pyridylcarbinol, at the same dose, was inhibitory, but less so than III and IV. The experimental process involved the reaction of Pyridine-3-sulfonic acid(cas: 636-73-7).Related Products of 636-73-7

The Article related to nicotinate nicotinamide transport metabolism bordetella, pyridinecarboxaldehyde bordetella nicotinamide uptake inhibition, pyridinealdoxime bordetella nicotinamide uptake inhibition and other aspects.Related Products of 636-73-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Pop, Flavia; Melan, Caroline; Danila, Ion; Linares, Mathieu; Beljonne, David; Amabilino, David B.; Avarvari, Narcis published an article in 2014, the title of the article was Hierarchical Self-Assembly of Supramolecular Helical Fibres from Amphiphilic C3-Symmetrical Functional Tris(tetrathiafulvalenes).Name: [2,2′-Bipyridine]-3,3′-diamine And the article contains the following content:

The preparation and self-assembly of the enantiomers of C3-sym. compounds incorporating three tetrathiafulvalene (TTF) residues is reported. The chiral citronellyl and dihydrocitronellyl alkyl chains lead to helical one dimensional stacks in solution Mol. mechanics and dynamics simulations combined with exptl. and theor. CD support the observed helicity in solution These stacks self-assemble to give fibers that have morphologies that depend on the nature of the chiral alkyl group and the medium in which the compounds aggregate. An inversion of macroscopic helical morphol. of the citronellyl compound is observed when compared to analogous 2-methylbutyl chains, which is presumably a result of the stereogenic center being further away from the core of the mol. This composition still allows both morphologies to be observed, whereas an achiral compound shows no helicity. The morphol. of the fibers also depends on the flexibility at the chain ends of the amphiphilic components, as there is not such an apparently persistent helical morphol. for the dihydrocitronellyl derivative as for that prepared from citronellyl chains. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Name: [2,2′-Bipyridine]-3,3′-diamine

The Article related to hierarchical self assembly supramol helix amphiphilic c3 sym tetrathiafulvalene, c3 symmetry, circular dichroism, electronic microscopy, supramolecular chirality, tetrathiafulvalene and other aspects.Name: [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Gumbau-Brisa, R.; Hayward, J. J.; Wallis, J. D.; Rawson, J. M.; Pilkington, M. published an article in 2016, the title of the article was Structural insights into the coordination chemistry and reactivity of a 3,3′-bis-imine-2,2′-bipyridine ligand.Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine And the article contains the following content:

The coordination chem. of ligand L8 Schiff-base derived from 6,6′-diamine-2,2′-bipyridine and salicylaldehyde, with Lewis acidic metal ions affords mononuclear [Sn(L9)Cl4] (1) and two paramagnetic dimers [Cu(L9)(sal)]2(ClO4)2, (2) and [Mn(L9)Cl2(EtOH)]2 (3). The x-ray crystal structures of 1-3 reveal a propensity for L8 to undergo metal catalyzed hydrolysis and cyclization to the diazepine ligand L9. Theor. calculations on L8 and a model Sn(IV) complex reveal that coordination to a metal ion weakens the imine bonds, rendering them more susceptible to hydrolysis reactions and/or attack by nucleophiles. In contrast, reaction of L8 with FeCl3 in the presence of base affords the partial hydrolysis product [Fe(L10)2]Cl·CH3CN (4). Tuning the reaction conditions via the addition of a 2nd base slows down the hydrolysis of the ligand sufficiently to afford a few crystals of the μ2-oxo diferric complex (μ-O)[Fe(L8)]2·2CH3CN (5) in which intact L8 coordinates to the Fe(III) in a bis-bidentate manner through a deprotonated salicyl oxygen and a bis-imine nitrogen lone pair, with the nitrogen atoms of its 2,2′-bipyridine remaining uncoordinated. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine

The Article related to tin transition metal schiff diaminebipyridine salicylaldehyde diazepine complex preparation, crystal structure tin transition metal schiff diaminebipyridine salicylaldehyde diazepine and other aspects.Recommanded Product: [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 27, 2003, Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradel, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane published a patent.Name: N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine The title of the patent was Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase. And the patent contained the following:

The invention relates to triazines (shown as I; variables defined below; e.g. 4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide) and Cy3-X1-Ar2-(C(R5):C(R6))qC(O)NH-Ay2 (II; variables defined below; e.g. ), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data included for many I and II). The invention provides compounds and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cy1 and -L1-Cy1 (L1 = C1-C6 alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cy1 = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH2-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cy1, and -L1-Cy1). Y2 = chem. bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl); Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH2- is replaced with -NH-, and more preferably -NH-CH2), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ay1 and CH:CHC(O)NH-Ay1 (Ay1 = aryl or heteroaryl, each of which is optionally substituted). For II: Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chem. bond, C1-C4 alkylene, C2-C4 alkenylene, and C2-C4 alkynylene, provided that L2 is not a chem. bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)2-, -S(O)2N(R7)-, -N(R7)S(O)2-, -C(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-O- and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 = M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH2-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of preparation are not claimed, hundreds of example preparations are included. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Name: N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

The Article related to carboxamide preparation inhibitor histone deacetylase proliferative disease treatment, triazinyl carboxamide preparation inhibitor histone deacetylase proliferative disease treatment and other aspects.Name: N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 31, 2021, Sun, Ji-yun; Kumata, Katsushi; Chen, Zhen; Zhang, Yi-ding; Chen, Jia-hui; Hatori, Akiko; Fu, Hua-long; Rong, Jian; Deng, Xiao-yun; Yamasaki, Tomoteru; Xie, Lin; Hu, Kuan; Fujinaga, Masayuki; Yu, Qing-zhen; Shao, Tuo; Collier, Thomas Lee; Josephson, Lee; Shao, Yi-han; Du, Yun-fei; Wang, Lu; Xu, Hao; Zhang, Ming-rong; Liang, Steven H. published an article.Electric Literature of 1820711-82-7 The title of the article was Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators. And the article contained the following:

Abstract: N-methyl-D-aspartate receptors (NMDARs) play critical roles in the physiol. function of the mammalian central nervous system (CNS), including learning, memory, and synaptic plasticity, through modulating excitatory neurotransmission. Attributed to etiopathol. of various CNS disorders and neurodegenerative diseases, GluN2B is one of the most well-studied subtypes in preclin. and clin. studies on NMDARs. Herein, we report the synthesis and preclin. evaluation of two 11C-labeled GluN2B-selective neg. allosteric modulators (NAMs) containing N,N-dimethyl-2-(1H-pyrrolo[3,2-b]pyridin-1-yl)acetamides for positron emission tomog. (PET) imaging. Two PET ligands, namely [11C]31 and [11C]37 (also called N2B-1810 and N2B-1903, resp.) were labeled with [11C]CH3I in good radiochem. yields (decay-corrected 28% and 32% relative to starting [11C]CO2, resp.), high radiochem. purity (>99%) and high molar activity (>74 GBq/μmol). In particular, PET ligand [11C]31 demonstrated moderate specific binding to GluN2B subtype by in vitro autoradiog. studies. However, because in vivo PET imaging studies showed limited brain uptake of [11C]31 (up to 0.5 SUV), further medicinal chem. and ADME optimization are necessary for this chemotype attributed to low binding specificity and rapid metabolism in vivo. The experimental process involved the reaction of tert-Butyl 6-bromo-1H-pyrrolo[3,2-b]pyridine-1-carboxylate(cas: 1820711-82-7).Electric Literature of 1820711-82-7

The Article related to glun2b receptor neg allosteric modulator pet imaging radiotracer brain, glun2b subunit, nmdars, carbon-11, ionotropic glutamate receptors (iglurs), positron emission tomography (pet) and other aspects.Electric Literature of 1820711-82-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 30, 2019, Silverblatt, Joshua A.; Ziff, Oliver J.; Dancy, Luke; Daniel, Allen; Carter, Ben; Scott, Paul; Sado, Daniel M.; Shah, Ajay; Bromage, Daniel I. published an article.Synthetic Route of 132-20-7 The title of the article was Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis. And the article contained the following:

Meta-anal. of current myocarditis guidelines do not advocate treatment to prevent myocardial injury and scar deposition in patients with myocarditis and normal left ventricular ejection fraction. We aimed to ascertain the utility of beta blockers, calcium channel blockers and antagonists of the renin-angiotensin system in ameliorating myocardial injury, scar formation and calcification in animal in vivo models of myocarditis. The project was prospectively registered with the PROSPERO database of systematic reviews (CRD42018089336). Primary outcomes (necrosis, fibrosis and calcification) were meta-analyzed with random-effects modeling. 52 Studies were systematically reviewed. Meta-anal. was performed compared with untreated controls. In each study, we identified all independent comparisons of treatment vs. control groups. The pooled weighted mean difference (WMD) indicated treatment reduced necrosis by 16.9% (71 controlled analyses, 95% CI 13.2-20.7%; P < 0.001), however there was less evidence of an effect after accounting for publication bias. Treatment led to a 12.8% reduction in fibrosis (73 controlled analyses, 95% CI 7.6-18.0%; P < 0.001). After accounting for publication bias this was attenuated to 7.8% but remained significant. Treatment reduced calcification by 4.1% (28 controlled analyses, 95% CI 0.2-8.0%; P < 0.0395). We observed significant heterogeneity in effect size in all primary endpoints, which was predominantly driven by differences between drug categories. Beta blockers and angiotensin-converting enzyme (ACE) inhibitors were the only agents that were effective for both necrosis and fibrosis, while only ACE inhibitors had a significant effect on calcification. This study provides evidence for a role for ACE inhibitors and beta blockers to prevent myocardial injury and scar deposition in in vivo models of myocarditis. There is a need for further well-designed studies to assess the translational application of these treatments. The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).Synthetic Route of 132-20-7

The Article related to meta analysis myocardial injury myocarditis beta calcium channel blocker, calcification, drug treatment, fibrosis, meta-analysis, myocarditis, necrosis, remodelling, systematic review and other aspects.Synthetic Route of 132-20-7

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Padivitage, Nilusha L.; Smuts, Jonathan P.; Breitbach, Zachary S.; Armstrong, Daniel W.; Berthod, Alain published an article in 2015, the title of the article was Preparation and Evaluation of HPLC Chiral Stationary Phases Based on Cationic/Basic Derivatives of Cyclofructan 6.Category: pyridine-derivatives And the article contains the following content:

The cyclofructan 6 (CF6) macrocyclic-oligosaccharide was derivatized with five different substituents able to bear pos. charges: Pr imidazole, Me benzimidazole, di-Me aminopropyl, pyridine, and di-Me aminophenyl. The derivatized cyclofructans were reacted with triethoxysilyl-propylisocyanate as a linker to bond them to 5μm spherical silica gel particles and then used to prepare liquid chromatog. columns. The bonded silica particles were analyzed to establish the bonding densities. A set of 34 chiral compounds including acids, neutral compounds, and bases was tested with nine different mobile phase compositions including two reverse phase (RP) acetonitrile/pH 4 buffer, three polar organic (PO) acetonitrile/methanol, and four normal phase (NP) heptane/ethanol mobile phases. No compounds could be separated in the RP mode. Eight compounds only could be enantiosepd. in the PO mode and 21 compounds in the NP mode. The most effective chiral stationary phase was the Pr imidazole derivatized CF6 phase, provided no more than six imidazole substituents and two linkers are attached per CF6 unit. The experimental process involved the reaction of N,N-Dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine maleate(cas: 132-20-7).Category: pyridine-derivatives

The Article related to cyclofructan cationic derivative hplc chiral stationary phase enantiomer separation, liquid chromatography, cationic derivatives, chiral separation, cyclofructan, enantiomer separation and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem